This compound is a spirocyclic pharmaceutical intermediate featuring a hydroxy group, a methylsulfanyl substituent, and a tert-butyl ester protecting group. Its structure contains multiple aromatic and heterocyclic rings, and it is primarily used in the synthesis of kinase inhibitors for research and pharmaceutical manufacturing.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 2170746-97-9
Tert-butyl 4-methylsulfanyl-10-oxo-8-(trifluoromethylsulfonyloxy)spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate
n.a
5-[4-[[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furancarboxaldehyde
Pharmaceutical intermediate for kinase inhibitors
3-Amino-5-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile
Pharmaceutical intermediate for kinase inhibitors
2-(1-(Ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile
Pharmaceutical intermediate for kinase inhibitors
2-Bromo-5-[(4-methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazine
Pharmaceutical intermediate for kinase inhibitors
Trilaciclib Impurity 3
Pharmaceutical impurity reference standard
Benzyl (2S)-2-{8-aminoimidazo[1,5-a]pyrazin-3-yl}pyrrolidine-1-carboxylate
Pharmaceutical intermediate for impurity synthesis
Fmoc-Ile-Aib-OH
Peptide building block for synthesis
tert-butyl 8-hydroxy-4-methylsulfanyl-10-oxospiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate
WISYVWISRLRKNF-UHFFFAOYSA-N
CC(C)(C)OC(=O)N1CC2(CCCCC2)N3C(=C(C4=CN=C(N=C43)SC)O)C1=O
—